The 3 domestically produced Class 1 new drug TOP10 companies are amazing...

A few days ago, Renfu Pharmaceutical's Class 1 new drug, propofol disodium phosphate for injection, was approved for marketing.

Since 2011, domestic Class 1 new drugs have been approved as TOP10 companies

Source: Meinenet MED2.

60 domestically produced Class 1 new drugs involve more than 40 companies (in terms of the group), and 10 companies including Hengrui, Hausen, BeiGene, Simcere, Beida, Gery, and Hutchison Whampoa have been approved for 2 varieties And above.

Domestic Class 1 new drugs with sales exceeding 1 billion yuan in 2020

Note: Domestic sales refer to the total sales of Chinese public medical institutions and physical pharmacies in Chinese cities

Source: Mi Nei Net Database

The total sales of 11 varieties in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies in 2020 will exceed 1 billion yuan.

A few days ago (April 30), the National Medical Insurance Bureau announced that as of April 15th, 19 newly negotiated drugs with clinical priority and low substitutability entered 3324 designated medical institutions, including 1,417 medical institutions and retail pharmacies.

"Innovative Drug One Brother" 6 new category 1 new drugs are dazzling, with 3 annual sales exceeding 1 billion

Hengrui Medicine has been approved for the listing of 6 Class 1 new drugs, and the total domestic sales in 2020 will exceed 8 billion yuan.

PD-1 carrelizumab has not been on the market for a long time, but it has quickly become Hengrui's blockbuster product.

Fluzoparib, approved in 2020, is the first domestically produced PARP inhibitor.

At present, Hengrui Medicine has a number of Class 1 new drugs under review and approval, including SHR6390 (CDK4/6 selective inhibitor), Hetropopaethanolamine (TPOR agonist), Retagliptin phosphate (DPP) -4 inhibitor), proline Henggliflozin (SGLT2 inhibitor), linpril (PI3Kδ selective inhibitor).

Hausen Pharmaceuticals was approved for 4 Class 1 new drugs, setting a number of domestic firsts

Hausen has 4 Class 1 new drugs approved for marketing.

Flumatinib mesylate is the first domestically produced new second-generation BCR-ABL tyrosine kinase inhibitor.

Polyethylene glycol loxenatide is the first domestically produced long-acting GLP-1 receptor agonist and the world's first PEGylated long-acting GLP-1 receptor agonist.

Ametinib mesylate is the first domestically produced third-generation EGFR-TKI inhibitor, directly against osimertinib (global sales of more than 4 billion U.

At present, Haosen Pharmaceuticals still has one new class 1 drug submitted for marketing.

Three new class 1 drugs have been approved one after another, BeiGene enters the harvest period

As the company with the highest R&D investment among listed pharmaceutical companies, BeiGene’s R&D achievements have been fulfilled one after another.

Tilelizumab is the fourth domestically produced PD-1 approved for listing in China, and it is the company's first category 1 new drug approved for listing.

Zebutinib is a BTK inhibitor independently developed by BeiGene and was approved by the FDA in November 2019, bringing a "zero breakthrough" for Chinese original new drugs to go overseas; in June 2020, it was approved by the National Food and Drug Administration for marketing , Becoming the first domestically approved BTK inhibitor with domestic sales exceeding 200 million yuan in 2020.
At present, the product has been approved for 2 indications, and the third indication has been reported for production.

Among the new drugs being developed, the imported licensed drugs carfilzomib, belintouximab, stuximab, and dituximab have been applied for listing and will continue to enter the Chinese market in the future.

Source: Mi Nei Net Database